RT Journal Article T1 Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up A1 Perez-de-Isla, Leopoldo A1 Alonso, Rodrigo A1 Watts, Gerald F. A1 Mata, Nelva A1 Saltijeral-Cerezo, Adriana A1 Muniz, Ovidio A1 Fuentes, Francisco A1 Diaz-Diaz, Jose Luis A1 de-Andres, Raimundo A1 Zambon, Daniel A1 Rubio-Marin, Patricia A1 Barba-Romero, Miguel A. A1 Saenz, Pedro A1 Sanchez-Munoz-Torrero, Juan F. A1 Martinez-Faedo, Ceferino A1 Miramontes-Gonzalez, Jose P. A1 Badimon, Lina A1 Mata, Pedro K1 Guidance K1 Management K1 Ezetimibe K1 Mortality K1 Efficacy K1 Therapy K1 Disease K1 Cohort K1 Risk K1 Care K1 Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz K1 Cardiovascular disease K1 LDL-receptor mutations K1 Lipid-lowering therapy K1 Low-density lipoprotein cholesterol AB BACKGROUND Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data on attainment of treatment targets; large registries that reflect real-life clinical practice can uniquely provide this information.OBJECTIVES We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients enrolled in a large national registry.METHODS The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing registry of molecularly defined patients with heterozygous FH treated in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was investigated in relation to use of lipid-lowering therapy (LLT).RESULTS The study recruited 4,132 individuals (3,745 of whom were >= 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target = 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target <100 mg/dl was reached by only 11.2% of patients. At follow-up, there was a significant increasein the use of ezetimibe, drug combinations with statins, and maximal LLT. The presence of type 2 diabetes mellitus, adefective allele mutation, ezetimibe use, and the absence of previous ASCVD were predictors of the attainment ofLDL-C goals. CONCLUSIONS Despite the use of intensified LLT, many FH patients continue to experience high plasma LDL-C levelsand, consequently, do not achieve recommended treatment targets. Type of LDL-receptor mutation, use of ezetimibe,coexistent diabetes, and ASCVD status can bear significantly on the likelihood of attaining LDL-C treatment goals. PB Elsevier SN 0735-1097 YR 2016 FD 2016-01-05 LK http://hdl.handle.net/10668/18806 UL http://hdl.handle.net/10668/18806 LA en NO Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. J Am Coll Cardiol. 2016 Mar 22;67(11):1278-85 DS RISalud RD Jul 7, 2025